2021 Essex County Council election

BluePearl Specialty and Emergency Pet Hospital Announces Multi-Year Investments to Empower its Employees and Create a Sustainable Profession

Retrieved on: 
Tuesday, August 10, 2021
People, Associate, Patient, Education, Quality of life, CVT, Program, PETS, Knowledge, LGBT Mormon people and organizations, Hospital, BluePearl Veterinary Partners, 2021 Essex County Council election, Growth, Organization, Culture, Industry, Partnership, Veterinarian, Book, Medicine

BluePearl's CareerTrax tracks Associates' skillset development for career advancement (leveling up) and gives Associates full transparency into requirements for each role, level, and specialty.

Key Points: 
  • BluePearl's CareerTrax tracks Associates' skillset development for career advancement (leveling up) and gives Associates full transparency into requirements for each role, level, and specialty.
  • Founded in 1996, BluePearl is one of the largest specialty and emergency veterinary practices in the U.S. today.
  • BluePearl clinicians also participate in clinical studies to discover new treatments and procedures that improve pet health.
  • Steve Ireland, BluePearl Specialty and Emergency Pet Hospital, 813.560.0029, [email protected]
    Laura Fourniotis, BluePearl Specialty and Emergency Pet Hospital, 813.327.6937, [email protected]

Adrian Paraschiv, MD, FACP, FHM is recognized by Continental Who's Who

Retrieved on: 
Monday, August 9, 2021
Continental, 2021 Essex County Council election, Liver, NewYork-Presbyterian Brooklyn Methodist Hospital, Internal medicine, BS, Health, Malcolm Baldrige National Quality Award, Coronary artery disease, Asthma, Hospital medicine, Information technology, Methodist Hospital, MD, Chronic obstructive pulmonary disease, Informatics, Stroke, Venous thrombosis, EMR, Multimedia, Society of Hospital Medicine, Documentation, Physics, Patient, Hotel manager, FHM, American Board of Commissioners for Foreign Missions, Society, American College, View, Mathematics, American College of Physicians, Skiing, Diabetes, Quality assurance, Heart failure, FACP, Saint Barnabas Medical Center, Hospital, Medical device, Medicine, Pharmaceutical industry

Dr. Paraschiv is a board-certified Internist and Administrator at Garnet Health Medical Center in Middletown, NY.

Key Points: 
  • Dr. Paraschiv is a board-certified Internist and Administrator at Garnet Health Medical Center in Middletown, NY.
  • His practice promotes the overall well-being of patients needing internal medical care in a hospital setting.
  • Alongside his medical work, Dr. Paraschiv operates in an administrative capacity as the Garnet Health Doctors Hospitalist Division's Associate Program Director.
  • He would like to dedicate this recognition to honor his previous partner and colleague Diane Spagnoli-Pine, MD.

aTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress

Retrieved on: 
Monday, August 9, 2021
2021 Essex County Council election, Ohio State University, LIFE, Private Securities Litigation Reform Act, Ohio State University Wexner Medical Center, Sarcoidosis, GLOBE, Neuropilin, COVID-19, SAN, CA, FC, Cytokine, Interstitial lung disease, Risk, RNA transfection, Patient, SEC, Biology, Forward-looking statement, Inflammation, ATyr Pharma, Safety, Research, Goal, Annual report, Pharmaceutical industry

aTyr Pharma, San Diego, CA, Ohio State University Wexner Medical Center, Columbus, Ohio.

Key Points: 
  • aTyr Pharma, San Diego, CA, Ohio State University Wexner Medical Center, Columbus, Ohio.
  • Full text of the abstracts will be available on the conference website on August 23, 2021.
    aTyr is developing ATYR1923 as a potential therapeutic for patients with severe inflammatory lung diseases.
  • aTyr has completed enrollment in a proof-of-concept Phase 1b/2a trial evaluating ATYR1923 in patients with pulmonary sarcoidosis.
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

Quanterix Simoa® Technology Powers Breakthrough Alzheimer’s Disease Research Presented by Eli Lilly and Company at Alzheimer’s Association International Conference (AAIC) 2021

Retrieved on: 
Friday, August 6, 2021
Technology, Other Health, Health, Pharmaceutical, Oncology, Other Science, Other Technology, Research, Infectious Diseases, Software, Science, Company, Alzheimer's disease, Corporation, Donanemab, Private Securities Litigation Reform Act, Clinical trial, U.S. Securities and Exchange Commission, Roman Hrusovsky, Dementia, Risk, Biomarker, Population, AD, Infection, Solution, Longevity, NASDAQ, Antibody, Technology, Patient, Inflammation, JAMA Neurology, Neurodegeneration, Eli Lilly and Company, Research, Tau, Paced Auditory Serial Addition Test, Founder, Lilly, Doctor of Philosophy, AAIC, Science, 2021 Essex County Council election, Diagnosis, Neurology, Quality of life, Cardiology, HIV disease progression rates, PPH, News, Therapy, Triage, Forward-looking statement, Pharmaceutical industry, Medical imaging

The study utilized Quanterix Simoa HD-X technology and assays to measure P-tau217 (tau phosphorylated at threonine 217), using antibodies developed by Lilly.

Key Points: 
  • The study utilized Quanterix Simoa HD-X technology and assays to measure P-tau217 (tau phosphorylated at threonine 217), using antibodies developed by Lilly.
  • Our groundbreaking Simoa technology continues to facilitate key Alzheimers disease research, as evidenced by more than 80 abstracts based on Simoa technology presented at AAIC 2021, one of the most pivotal and innovative events for the Alzheimers community.
  • Additional information on the TRAILBLAZER-ALZ study and the reported results can be found in Lillys July 29, 2021 AAIC press release .
  • Research suggests that P-tau217, a form of the tau protein, may be a critically important biomarker for Alzheimers disease (AD) diagnosis.

Verona Pharma Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 5, 2021
Company, Investor, Conference call, Pharming, Maintenance, Critical Care Medicine (journal), International Journal of Chronic Obstructive Pulmonary Disease, EDT, Government, Infection, Canadian International Council, Pharmacokinetics, American Journal of Respiratory and Critical Care Medicine, Patient, COVID-19, 2021 Essex County Council election, Quality of life, GLOBE, Investigational New Drug, Sale, ATS, BST, Vault RNA, Nasdaq, China, Degenerative disease, D, Fluconazole, Hospital, Research, G&A, Â, Achievement, Communications satellite, Fine chemical, Pharmaceutical industry

LONDON and RALEIGH, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended June 30, 2021, and provides a corporate update.

Key Points: 
  • Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST
    LONDON and RALEIGH, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma or the Company), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended June 30, 2021, and provides a corporate update.
  • In June 2021, Verona Pharma and Nuance Pharma entered into a $219.0 million strategic collaboration to develop and commercialize ensifentrine in Greater China.
  • Verona Pharma will host an investment community conference call at 8:30 a.m.EDT / 1:30 p.m. BST on Thursday, August 5, 2021 to discuss the second quarter 2021 financial results and the corporate update.
  • An electronic copy of the second quarter 2021 results press release will also be made available today on the Companys website.